Polyploidization in megakaryocytes is achieved by endomitosis, a specialized cell cycle in which DNA replication is followed by aberrant mitosis. Typical mitotic regulators such as Aurora kinases or Cdk1 are dispensable for megakaryocyte maturation, and inhibition of mitotic kinases may in fact promote megakaryocyte maturation. However, we show here that Polo-like kinase 1 (Plk1) is required for endomitosis and ablation of 
Introduction
Megakaryocytes are bone marrow cells specialized in the generation of platelets 1 . Once committed to differentiation, megakaryocyte progenitor cells undergo several rounds of endomitotic cell cycles in which the latest stages of mitosis are aborted to render polyploid cells. After genome duplication, megakaryocytes enter mitosis by breaking down the nuclear envelope and condensing chromosomes, but they exit mitosis in the absence of complete karyokinesis generating polylobulated nuclei 1, 2 . This process is thought to be mediated by impaired furrow formation due to impaired RhoA activity and defective formation of the actomyosin ring required for cytokinesis 3, 4 . The increase in ploidy is a necessary component of megakaryocyte differentiation and only highploidy cells are able to shed platelets efficiently. Although the reason for this requirement is not completely clear, the increase in ploidy accompanies the increase in cellular volume and this may provide cells with sufficient cytoplasmic volume to generate a large number of platelets 1, 5, 6 .
Since mitosis is aborted in its later stages, the requirement for mitotic regulators during megakaryocyte polyploidization has been a matter of debate. Earlier work in cell lines suggested defective activity of mitotic cyclins and its catalytic partner cyclindependent kinases (Cdk1)[reviewed in Ref. 5] . Recent expression data indicate that the mitotic machinery is normally expressed in megakaryocytes whereas it is downregulated in endocycling cells, i.e. cells that polyploidize through successive cycles in the complete absence of mitotic features such as trophoblast giant cells 7 . Yet, although specific mitotic kinases such as Aurora A or Aurora B or its partners are
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Plk1 is a member of the Plk family involved in centrosome maturation, formation of the mitotic spindle, microtubule-chromosome attachment, as well in cytokinesis [14] [15] [16] [17] . Similarly to Aurora A inhibition, inhibition of Plk1 results in defective centrosome maturation and spindle formation. Due to its critical functions in the mitotic cell cycle and its expression in human tumors, Plk1 has been proposed as a cancer target and recent clinical trials with Plk1 inhibitors have indeed shown significant therapeutic effect in hematopoietic tumors 15, [18] [19] [20] [21] . These findings have been used to propose new therapeutic strategies based on the idea that inhibition of mitotic kinases, including members of the Cdk, Aurora or Polo-like kinase (Plk) family, should impair growth of leukemia [e.g. acute megakaryocytic leukemia (AMKL)] cells without affecting polyploidization or function of normal megakaryocytes 9, 22 , a feature that could protect patients from thrombocytopenia, a major side effect of anti-proliferative therapies.
To understand the relevance of Plk1 during megakaryocyte differentiation we have analyzed the effect of the specific genetic ablation of the murine Plk1 locus using a new conditional knockout model recently generated in our laboratory. Contrary to the inhibition of Aurora kinases, elimination of Plk1 results in strong defects in megakaryocyte maturation in vivo. Plk1 deficiency prevents megakaryocyte polyploidization as a result of the activation of the Spindle Assembly Checkpoint (SAC) in these cells. This results in prolonged mitotic arrest and death of Plk1-null megakaryoyctes resulting in severe thrombocytopenia in vivo. These data highlight the functional relevance of the SAC in endomitotic megakaryocytes and add a note of caution in the general use of mitotic kinase inhibitors in therapeutic strategies based on polyploidization regulators.
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Materials and Methods
Mouse models and histopathological analysis. A 0.8-kb fragment containing the murine Plk1 exon 2 was flanked with loxP sites and followed by a PGK-neomycin phosphotransferase (neo) cassette, flanked by frt sites, for positive selection of ES cell clones. Recombinant clones were selected by southern blot and the neo cassette was removed using Flp recombinase to generate the Plk1 conditional allele [Plk1(lox)] (P.W. and G.d.C., submitted for publication). Pf4-Cre mice and the megakaryocytespecific Cdc20 conditional knockout were described previously 12 , 23 . All animals were maintained in a mixed 129/Sv (25%) times CD1 (25%) times C57BL/6J (50%) background. Mice were housed in the pathogen-free animal facility of the Centro Nacional de Investigaciones Oncológicas (CNIO, Madrid) following the animal care standards of the institution. All animal protocols were approved by the local committee for animal care and research. Thrombopoietin (TPO 1.2 μg/mouse) was injected subcutaneously into 8-12-week-old mice and platelet counts were analyzed 4 days later. In these assays, Taxol was used at 300 nM, the Plk1 inhibitor BI2536 at 100nM, and reversine was used at 1 μM for inhibition of the SAC kinase Mps1 Statistical analysis. Statistical analysis was carried out using Prism 5 (GraphPad). All statistical tests were performed using two-sided, unpaired Student's t-tests. Data with p < 0.05 were considered statistically significant. In most figures, *, p<0.05; **, p<0.01; ***, p<0.001.
Results

Lack of Plk1 results in impaired megakaryocyte maturation
To specifically eliminate Plk1 in megakaryocytes we made use of a Plk1 conditional allele [Plk1(lox)], recently generated in our laboratory (see Methods), and Pf4-Cre transgenic mice in which the Cre recombinase is expressed under Platelet factor 4 regulatory transcriptional sequences leading to efficient recombination in medium and high-ploidy megakaryocytes 23 , 12 . were however resistant to treatment with TPO suggesting a defect in the process that leads to the generation of platelets from megakaryocyte progenitors ( Figure S4 ).
Defective mitotic exit in the absence of Plk1
To better follow megakaryocyte polyploidization, we monitored megakaryocyte maturation using time-lapse microscopy in Lin bone marrow cells after treatment with 25 . Cell cycle progression in control megakaryocytes can be monitored by levels of geminin, which is low in G1 and high in S-phase-G2-M, and the pattern of histone which allows following chromosome condensation in mitosis (Figure 3a ). Since geminin is exclusively nuclear during interphase, endomitosis can also be detected by pan-cellular localization of geminin in these cells as a consequence of nuclear envelope breakdown 12 .
In the absence of Plk1, cells entered normally into mitosis; i.e.
chromosomes condensed and geminin signal was pan-cellular due to the absence of nuclear envelope. However, geminin signal remained high for more than 20 h during mitosis (chromosomes condensed and pan-cellular signal of geminin) until cells died (Figure 3b) . In a few cases, Plk1(Δ/Δ) megakaryocytes were able to exit from mitosis but they usually died in the following interphase before they were able to start a new cycle of geminin expression (Figure 3b ,c). Whether this death is a direct consequence of Plk1 ablation or is partially due to the intense manipulation of these cultured megakaryocytes is not clear at present. On average, Plk1-deficient megakaryocytes spent about 30 h in mitosis, whereas the duration of mitosis in normal megakaryocytes was 57 ± 14 min (Figure 3d ). Interestingly, this arrest in mitosis was even longer than the one obtained after genetic ablation of Cdc20, a model in which mitotic exit is prevented leading to metaphase arrest for long periods of time until they die 12, 26 . For
Lack of
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Lack or inhibition of Plk1 results in a SAC-dependent mitotic arrest
The defects in centrosome maturation and spindle structure suggested that mitotic arrest in Plk1-deficient megakaryocytes could be a consequence of an active SAC. This mitotic checkpoint has been shown to be present in megakaryocytes using Cdc20 as an indirect readout 27 , although its relevance has not been established given the lack of genome segregation into separate cells. We therefore monitored the presence of two Figure S6 ). In Plk1-deficient cells or in the presence of BI2536, reversine induced mitotic exit giving rise to cells with interphasic ring nuclei or in which chromosomes formed multiple curved nuclei around the collapsed spindles (Figure 6a,b) . Reversine, however, had no effect in the mitotic arrest imposed by the lack of Cdc20 (Figure 6b,c) , a defect known to be SAC independent 26 . All together, these observations support the notion that lack of Plk1 prevents mitotic progression and megakaryocyte polyploidization by triggering a SAC-dependent response.
Discussion
The intrinsic differences between mitotic and endomitotic cell cycles have raised the possibility of using mitotic kinase inhibitors for treating hematological malignancies such as pro-megakaryocytic leukemias 22 . Many mitotic kinases such as Aurora A, Aurora B, Cdk1 or Plk1 are essential for the mitotic cell cycles and their genetic ablation results in lack of cell division in the embryo, most somatic cells and tumor cells 13, 15, 17, [28] [29] [30] . Yet, inhibition or genetic ablation of Aurora A or Aurora B does not perturb megakaryocyte polyploidization or maturation 9,11-13 . In addition, Cdk1 deficiency results in an alternative polyploidization mechanism based on endocycling that has no major effects in platelet production 12 .
In this manuscript, we report that contrary to these other mitotic kinases Plk1 is essential for megakaryocyte polyploidization and its ablation results in thrombocytopenia.
Endomitotic megakaryocytes are characterized by the presence of multipolar spindles with an asymmetrical distribution of chromosomes. Early studies in cell lines suggested that megakaryocytes can polyploidize in the presence of antimicrotubule poisons, suggesting the irrelevance of the SAC in these cells 31 . More recent data, however, showed that nocodazole arrests primary megakaryocytes in the presence of Cdc20 signal at the kinetochores indicating that the SAC may be activated in these cells in the presence of microtubule poisons 27, 32, 33 . Sister chromatid separation seems to occur asymmetrically towards the different poles, and chromosomes cluster into a ring around each aster suggesting that each chromosome ring may give rise to one lobe of the megakaryocytic nucleus 27 . The asymmetric segregation of chromosomes towards the multiple poles suggested that the SAC is permissive for the complex attachment of chromosomes to multipolar spindles in megakaryocytes 27 . That situation is altered in Plk1-deficient megakaryocytes, likely as a consequence of the formation of monopolar Figure S5 ). These defects in spindle formation likely lead to a checkpoint-dependent mitotic arrest that in most cases triggers cell death, showing that megakaryocytes can also monitor defects in spindle assembly using a functional SAC. The complexity of endomitosis likely requires multiple other pathways, in addition to the Plk1-SAC axis, to generate functional polyploid megakaryocytes with multilobulated nuclei. Yet, the similarities and differences between mitotic and endomitotic cell cycles remain mostly unknown.
The SAC is a complex network that inhibits the APC/C-Cdc20 activity, thus preventing securin and cyclin B degradation and delaying mitotic exit, in the presence of unattached kinetochores 34 . Yet, cells can be able to exit from mitosis even in the presence of an unsatisfied SAC due to a process known as mitotic slippage 35 . During this process, cyclin B1 is slowly degraded as a consequence of weak APC/C-Cdc20 activity and, in fact, mitotic slippage does not occur in Cdc20-null cells and cells arrest in mitosis until they die 26 . The fact that Plk1-deficient megakaryocytes arrest in mitosis for longer periods of time than Cdc20-deficient megakaryocytes before they die ( Figure   3 ) suggests that Cdc20 and Plk1 may have separate implications in the mechanisms that modulate cell death in mitosis. Indeed, Cdc20 is known to suppress apoptosis through targeting Bim for degradation, suggesting increased mitotic apoptosis in the absence of this APC/C cofactor 36 . It has also been recently reported that Plk1-dependent phosphorylation of caspase-8 may trigger the extrinsic apoptotic pathway during mitosis 37 . However, treatment of Cdc20-null cells with Plk1 inhibitors does not prolong survival during mitotic arrest (data not shown) and mitotic cell death has been proposed
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Owing to the essential role of Plk1 in the control of the cell cycle, Plk1 is considered as an attractive cancer target with some small-molecule inhibitors showing encouraging results in clinical trials 19, 20 . Volasertib (a BI2536 derivative also known as BI6727) has shown a significant effect in acute myeloid leukemia (AML) patients 39 , an effect that recently received a Breakthrough Therapy designation by the FDA promoting its evaluation in Phase III clinical trials. Volasertib has also been tested in clinical trials in solid malignancies, in which the most common dose-limiting effects are thrombocytopenia and neutropenia 40, 41 . These problems may be due to specific effects in progenitors cells or to the fact that Plk1 inhibitors can inhibit other kinases at specific doses 42, 43 . However, our conditional knockout model suggests that Plk1 inhibition actually leads to defective polyploidization and cell death in megakaryocytes, a result with implications in the design of therapeutic protocols targeting this mitotic kinase. 
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